Stephen D. Hall, PhD

Key Publications

R          Rougée LRA, Bedwell DW, Hansen K, Abraham TL and Hall SD. Impact of heterotropic allosteric modulation on the time-dependent inhibition of CYP3A4. Drug Metab Dispos. 2023 Oct;51(10):1372-1380. doi: 10.1124/dmd.123.001382. 

2.                Datta-Mannan A, Shanks E, Yuen E, Jin Y, Rehmel J and Hall S. Identification of a safe and tolerable carbamazepine dosing paradigm that facilitates effective evaluation of CYP3A4 induction. Clin Pharmacol Ther. 2024 Oct;116(4):1034-1041. doi: 10.1002/cpt.3332. PMID: 38864600.

3.                Rougée LRA, Hegde PV, Shin K, Abraham TL, Bell A, Hall SD. Heterotropic allosteric modulation of CYP3A4 in vitro by progesterone: Evidence for improvement in prediction of time-dependent inhibition for macrolides. Drug Metab Dispos. 2025 Jan;53(1):100006. doi: 10.1124/dmd.124.001820. PMID: 39884818.

4.           Countant DE, Rehmel J, Edwards DM and Hall SD. A novel physiologically based pharmacokinetic model to estimate reduced CYP3A4 activity in cancer patients utilizing the neutrophil to lymphocyte ratio as an inflammatory marker. Eur J Clin Pharmacol. 2025 Jun;81(6):853-862. doi: 10.1007/s00228-025-03839-1. PMID: 40186675.

5.                Hegde P, Rodriguez B, Bell A, Hall SD and Rougée LRA. Improvement in static and dynamic projections of drug-drug interactions caused by cytochrome P4503A time-dependent inhibitors through in vitro allosteric modulation by progesterone. Drug Metab Dispos. 2025 Feb;53(2):100030. doi: 10.1016/j.dmd.2024.100030. PMID: 40023571.

6.                Datta-Mannan A, Czeskis B, Shanks E, Yuen E, Hall S, Rodriguez Cruz V and Cassidy K. Disposition and absolute bioavailability of oral imlunestrant in healthy females: a phase 1 open-label study. Clin Pharmacol Drug Develop 2025, Jun 24. doi: 10.1002/cpdd.1562. PMID: 40552410.

7.                Hegde PV, Rehmel J. Hall SD and Morse BL. Development of a physiologically based pharmacokinetic model to evaluate dosing regimens of cyclosporine as a precipitant of organic anion transporting polypeptide 1B (OATP1B)- and CYP3A4-mediated drug-drug interactions. J Clin Pharmacol 2025 Nov;65(11):1544-1560. doi: 10.1002/jcph.70076. PMID: 40646684.

8.                So GC, Li YG, Hall SD, Chien J, Payne CD, Posada MM, Piruzeli MLB, Jin Y. Comparison of regression and categorical analysis for pharmacokinetic data from renal impairment studies. Clin Pharmacol Ther. 2025 Oct;118(4):885-893. doi: 10.1002/cpt.3745. PMID: 40574578.

9.                Posada M, Schneck K, Morse B, Rougee L, Tham LS, Remel J, Thompson B, Stamatis S, Hall S and Dickinson G. A combined modeling approach to predict the effect of gastric emptying delay on the pharmacokinetics of small molecules. CPT Pharmacometrics Syst Pharmacol. 2025 Dec;14(12):2026-2039. doi: 10.1002/psp4.70101. PMID: 40842022.

10.             Tian DD, Hall SD, Chapman SC and Posada MM. Application of physiologically based pharmacokinetic modeling to support drug labeling: Prediction of CYP3A4-mediated pirtobrutinib-drug interactions. CPT Pharmacometrics Syst Pharmacol. 2025 Dec;14(12):2221-2231. doi: 10.1002/psp4.70134. PMID: 41165508.

11.             Datta-Mannan A, Shanks E, Yuen E, Cruz VR, Wang XA and Hall SD. Evaluation of pharmacokinetics and safety of imlunestrant in participants with hepatic impairment. J Clin Pharmacol 2026. DOI 10.1002/jcph.70181.

13.            Morse BL, Han B, Alberts JA, Posada MM, Dickinson GL and Hall SD. Verification of a physiologically-based pharmacokinetic model for predicting CYP3A4-mediated simvastatin and simvastatin acid drug-drug interactions. AAPS Journal, 2026.